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A B S T R A C T
Liver failure induced by systemic inﬂammatory response (SIRS) is often associated with mitochondrial
dysfunction but the mechanism linking SIRS and mitochondria-mediated liver failure is still a matter of
discussion. Current hypotheses suggest that causative events could be a drop in ATP synthesis, opening of
mitochondrial permeability transition pore, speciﬁc changes in mitochondrial morphology, impaired Ca2+
uptake, generation of mitochondrial reactive oxygen species (mtROS), turnover of mitochondria and imbalance
in electron supply to the respiratory chain. The aim of this review is to critically analyze existing hypotheses, in
order to highlight the most promising research lines helping to prevent liver failure induced by SIRS. Evaluation
of the literature shows that there is no consistent support that impaired Ca++ metabolism, electron transport
chain function and ultrastructure of mitochondria substantially contribute to liver failure. Moreover, our
analysis suggests that the drop in ATP levels has protective rather than a deleterious character. Recent data
suggest that the most critical mitochondrial event occurring upon SIRS is the release of mtROS in cytoplasm,
which can activate two speciﬁc intracellular signaling cascades. The ﬁrst is the mtROS-mediated activation of
NADPH-oxidase in liver macrophages and endothelial cells; the second is the acceleration of the expression of
inﬂammatory genes in hepatocytes. The signaling action of mtROS is strictly controlled in mitochondria at three
points, (i) at the site of ROS generation at complex I, (ii) the site of mtROS release in cytoplasm via permeability
transition pore, and (iii) interaction with speciﬁc kinases in cytoplasm. The systems controlling mtROS-signaling
include pro- and anti-inﬂammatory mediators, nitric oxide, Ca2+ and NADPH-oxidase. Analysis of the literature
suggests that further research should be focused on the impact of mtROS on organ failure induced by
inﬂammation and simultaneously providing a new theoretical basis for a targeted therapy of overwhelmed
inﬂammatory response.
1. Introduction
Mitochondrial dysfunction is often associated with multiple organ
failure (MOF), also referred to as multiple organ dysfunction syndrome
(MODS), induced by dysregulated systemic inﬂammatory response
(SIR). This pathological process, known as systemic inﬂammatory
response syndrome (SIRS) [1,2], is a common cascade accompanying
sepsis, trauma, burns, acute pancreatitis, ischemia, anaphylaxis and a
number of other diseases. Despite huge eﬀorts in the preclinical and
clinical research ﬁeld, pathogenesis of MOF is still not clearly under-
stood. Mitochondria are good candidates for playing a key role in this
process (reviewed in [3–5]), because they are essential components of
almost all eukaryotic cells, controlling several important cellular
functions, such as adenosine triphosphate (ATP) synthesis [6], regula-
tion of Ca++ homeostasis (reviewed in [7,8]), generation of reactive
oxygen species (ROS) (reviewed in [9–14]), activation of apoptosis
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(reviewed in [15]) and maintenance of intracellular redox potential.
The liver is one of the most susceptible organs to SIR [16], and
manifestation of liver dysfunction nearly always accompanies SIRS
[17]. Liver dysfunction, in turn, has dramatic consequences for the
whole body, inducing encephalopathy and cerebral edema, coagulo-
pathy, cardiovascular instability, respiratory and renal failure. Thus,
liver failure itself may induce MOF contributing to the lethal fate of SIR.
Consequently, prevention of liver dysfunction may ameliorate MOF/
MODS and improve clinical outcome and survival of patients with SIRS.
Liver failure has already been associated with mitochondrial
dysfunction [18,19] and inﬂammation (reviewed in [20]), both con-
tributing to a wide range of liver diseases. It has been shown that liver
inﬂammation, accompanied by the activation of immune cells in liver
tissue, is highly associated with hepatocellular carcinoma (reviewed in
[21]) and both alcoholic and non-alcoholic fatty liver diseases (re-
viewed in [22]). This suggests that mitochondrial dysfunction links
inﬂammation and liver failure.
Single studies usually address only selected mitochondrial functions
instead of providing a complete view in the context of inﬂammation.
This may be a reason for controversial data in the literature on the
pathologic impact of mitochondrial dysfunction, ranging from critical
to unimportant contribution to MOF/MODS. Another body of literature
suggests that an increase in mitochondrial turnover can be a sign of
mitochondrial dysfunction. These reports address the changes in
mitochondrial biogenesis [23–25] or/and autophagy [26]; (reviewed
in [27,28]), assuming that these changes are due to an increased
number of damaged/dysfunctional mitochondria, although the major-
ity of mitochondria appeared normal [29].
The aim of this review was to summarize data which conﬁrm or
contradict contribution of speciﬁc mitochondrial functions to liver
inﬂammation-induced organ failure. We analyzed the existing literature
hypothesizing that there are two prerequisites for the critical role of
mitochondrial dysfunction: (i) in all species which are susceptible to
SIR, either mitochondrial structure or function(s) will be impaired in a
similar manner, and (ii) if such impairment of mitochondrial function
(s) occurs, then a similar damage should cause liver failure also in other
pathological settings. Consequently, we consider that mechanisms of
liver dysfunction have similar pathways in humans and in animal
models.
1.1. Factors inducing acute SIR
The activation of the inﬂammatory response aims at combating
pathogens. This reaction is induced by so-called damage-associated
molecular pattern molecules (DAMPs) ([30], reviewed in [31]). A sub-
group of DAMPs are microbial pathogen-associated molecular pattern
molecules (PAMPs), such as structural components and nucleic acids of
viruses (reviewed in [32]), lipopolysaccharide (LPS) of Gram-negative
bacteria and peptidoglycan of Gram-positive bacteria (reviewed in
[33]). Both DAMPs and PAMPs activate innate and adaptive immune
responses predominantly via Toll-like receptors [34]. If the regulatory
mechanisms of the inﬂammation fail, the response may become
excessive, resulting in an overwhelming SIR. Although intended as a
self-protection program, this undesirable side eﬀect of the activation of
the immune system can cause damage to host cells and induce MODS/
MOF [35–37]. The mechanisms and pathways of MODS/MOF-inducing
systemic inﬂammatory response are subject of many investigations and
have already been extensively reviewed [38–44]. However, the exact
mechanisms underlying this deleterious eﬀect have still not clearly
been uncovered. As a matter of fact, many mammals develop MOF in
response to SIR, often leading to death. The mortality resulting from SIR
in the clinics is still very high [45–47], even in modern intensive care
units (reviewed in [4]).
The most common and reproducible way to induce SIR in experi-
mental animal models is administration of the pathogen-associated
molecular pattern molecule LPS, a Gram-negative bacterial toxin. To
date, the majority of mechanistic data on SIR are based on LPS models.
LPS induces MOF/MODS in diﬀerent species in a similar way as can be
characterized by elevated levels of circulating tissue damage markers
[48,49]. However, the concentrations of LPS needed to induce similar
damage as well as LD50 diﬀer from species to species (Table 1). A
prominent feature of LPS-induced SIR is a dose-dependent increase in
TNF-α levels. Xenobiotics, like D-Galactosamine sensitize hepatocytes
to apoptosis triggered by TNF-α, at least partly by a transcriptional
block. In such models, a small amount of LPS, as little as a few
micrograms/kg is able to induce severe hepatic damage [50]. More-
over, it was demonstrated that desensitization of the mitochondrial
permeability transition pore leads to a protection against liver injury
despite the maintained early TNF-α response [18]. Accordingly, on the
one hand, the above mentioned evidences demonstrate crucial role of
mitochondria in the process. On the other hand, inter-species diﬀer-
ences in the sensitivity to LPS might be connected to regulatory
characteristics of pore opening as well. If we consider mitochondrial
dysfunction as the critical issue for organ failure upon SIR, we expect
that diﬀerent doses of LPS in diﬀerent species should induce similar
changes in mitochondria. This consideration assumes that intracellular
signaling pathways mediating mitochondrial dysfunction, predomi-
nantly deﬁne the sensitivity to LPS and/or other DAMPs/PAMPs in
various species. The question whether or not diﬀerent species in fact
manifest similar impairment of liver mitochondria upon SIR will be
discussed in the following sections.
1.2. Eﬀect of SIR on mitochondrial structure
Ultra-structural alterations of liver mitochondria have been re-
ported from various animal species and as well as from septic patients.
Crouser et al. observed mild to moderate mitochondrial swelling, and
occasionally high-amplitude swelling with concomitant loss of mito-
chondrial membrane integrity in experiments with LPS-treated feline
[52]. They also reported that cyclosporine A pretreatment attenuated
LPS-induced mitochondrial ultra-structural abnormalities, suggesting
the involvement of permeability transition pore opening in mitochon-
drial swelling [53]. Hypertrophic mitochondria with reduced matrix
electron density and irregular cristae were also found in post-mortem
samples of critically ill patients [54]. In contrast, in another study, most
mitochondria of liver samples taken from septic patients were normal in
appearance, with intact organelle membrane [29]. These results were
conﬁrmed in a parallel study performed in mice. Livers of animals
subjected to cecal ligation and puncture (CLP) did not manifest
consistent abnormalities in mitochondria or nuclei [29]. Similarly, in
another CLP mice study, the vast majority of liver mitochondria in the
CLP group appeared normal, but increased number of intracellular
vacuoles were observed in hepatocytes and identiﬁed as autophago-
somes [55]. Furthermore, electron microscopic examination of isolated
liver mitochondria and liver tissue taken from rats subjected to LPS did
not evoke changes in the morphology of mitochondria neither in
isolated mitochondria nor in liver tissue [56]. Also an increased number
of intracellular vacuoles were observed in hepatocytes in close vicinity
to mitochondria in liver samples from LPS-treated rats, which were
identiﬁed as dilated endoplasmic reticulum (ER) [57].
Taken together, the majority of papers reported normal appearance
of mitochondria. However, intracellular vesicles have often been found
which were either interpreted as autophagosomes or dilated ER. Both of
Table 1
Susceptibility of diﬀerent species to LPS.
Species Pig Rabbit Dog Cat Rat Mouse
LD50 LPS (mg/kg, i.v.) 0.1** 0.5* 1.0* 2.2* 7.3* 7.7*
* Registry of toxic eﬀects of chemical substances [51].
** Maximum dose reported.
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these structures occurred being linked to mitochondria either function-
ally (autophagosomes) or spatially (dilated), suggesting that mitochon-
dria could be indirectly involved. The ﬁndings discussed above show
that there is no obvious coincidence between SIR and mitochondrial
ultra-structural changes, although the data indirectly imply involve-
ment of mitochondria. This suggests that not morphological but
functional changes in mitochondria may be the key for understanding
their pathological impact.
1.3. Respiratory function of mitochondria
Oxidative phosphorylation is the major function of mitochondria
providing energy in form of ATP for eukaryotic cells. The conversion
rate of adenosine diphosphate (ADP) to ATP linked to oxygen con-
sumption by the electron transport chain of mitochondria can easily be
evaluated by measuring the rate of mitochondrial respiration. State 3
respiration upon addition of ADP is directly linked to ATP synthesis and
this respiration state is determined in the majority of reports on
mitochondrial respiration. State 3 respiration can be determined only
in freshly isolated mitochondria [58] or in freshly prepared homo-
genates [59]. In frozen samples, only enzyme activities of single
respiratory chain complexes can be determined. This, however, does
not necessarily reﬂect the capacity to synthesize ATP. Tissue homo-
genate is probably the best way to estimate mitochondrial function,
because the isolation of mitochondria may theoretically lead to the loss
of a fraction of mitochondria, and additional damage (e.g. uncoupling).
Impaired respiratory function of mitochondria caused by LPS
treatment was predominantly determined in the pig [60], cat [52]
and baboon [61]. A recent review by Jeger et al. analyzed the existing
publications on rodents in experimental models of CLP, fecal peritonitis
and LPS challenge [62]. The authors summarized publications on
mitochondrial function in skeletal muscles, heart and liver. The
majority of publications showed that there were no changes in
mitochondrial function in any organ. However, in a few cases,
mitochondrial function was either improved or impaired. The majority
of published reports suggest that rodents are less susceptible to
mitochondrial dysfunction than porcine or feline although all these
species manifest MOF. Thus, there is no consistent coincidence between
SIR and respiratory dysfunction of mitochondria. The fact that respira-
tory function shows such strong variations from species to species and
between diﬀerent experimental models suggests that impairment may
not be due to primary but secondary processes occurring in SIR models.
In fact, SIR often leads to circulatory disturbances, resulting in impaired
tissue perfusion and secondary hypoxia. Consequently, not inﬂamma-
tory mediators directly, but circulatory failure accompanied by tissue
hypoxia may be the reason for SIR-induced mitochondrial impairment.
1.4. The impact of hypoxia and inﬂammatory mediators on mitochondria
upon SIRS
SIRS and sepsis is characterized by profound alterations of hemo-
dynamics. This is observed, on one hand, at the level of systemic
circulation, and on the other hand, in deteriorating tissue perfusion and
microcirculation disturbances [63,64], which are associated with a
poor outcome [65]. It is important to note that the survival in porcine
and sheep models of severe SIR is deﬁned not by direct eﬀect of
DAMPs/PAMPs on target cells, but by secondary circulatory eﬀects
such as increase in pulmonary arterial pressure probably via release of
endothelin-1 [66]. Acute pulmonary hypertension may cause respira-
tory failure, hypoxemia and hypoxia including liver tissue. SIR also
causes alteration in hepatic circulation at the level of both macro- and
microcirculation. As a speciﬁc feature of liver dysfunction, it has been
reported that severe SIR impairs portal venous blood inﬂow (reviewed
in [67]). Nitric oxide (NO), endothelin-1, and carbon monoxide are
considered to be the major factors disturbing liver circulation [68]. NO
can be the mediator which predominantly deﬁnes the vascular reaction
upon systemic inﬂammation. In contrast to pigs and humans, white
blood cells of rodents strongly express inducible nitric oxide synthase
(iNOS) causing excessive NO production. For example, there were no
increased NO levels upon SIRS in pigs [60], while a drastic increase in
NO levels was observed in a rat model [69]. By its well-known
vasorelaxant eﬀect, NO is able to lower vascular resistance. This
particular diﬀerence in the regulation of circulation upon inﬂammation
may be the reason for diﬀerent susceptibility of circulation to SIR in
diﬀerent species. Thus, circulatory failure can be the reason for cellular
damage and mitochondrial dysfunction upon SIR, even explaining the
diﬀerences between species. Beside circulatory failure, it was shown
that cellular damage can be induced by pro-inﬂammatory cytokines
such as tumor necrosis factor (TNF) alpha via induction of oxidative
stress (reviewed in [70]) or via intracellular signaling pathways of
acute-phase genes controlling cell damage [71]. Therefore, it is diﬃcult
to deﬁne exactly the reason for cellular damage in in vivo models.
Additionally, since hypoxia and inﬂammatory mediators occur and
interact simultaneously, it is very diﬃcult to separate their biological
eﬀects in vivo.
In a recent study, this issue was addressed in a model with precisely
cut liver slices (PCLS) [72]. PCLS are an ex vivo model of liver tissue,
maintaining cell-cell and cell-extracellular matrix interactions without
the inﬂuence of systemic processes. In this study, hypoxic incubation of
PCLS resulted in accumulation of liver cellular damage markers and
mitochondrial dysfunction, whereas incubation with inﬂammatory
mediators caused only release of liver damage markers. With regard
to the eﬀects of NO and hypoxia during inﬂammation, the rapid
diﬀusion of NO and its potent action as an inhibitor of mitochondrial
respiration has been proposed to perform a salutatory function,
extending the tissue oxygen gradient away from vessels to distal
hypoxic regions [73] There is evidence disturbances in this eﬀect
may adversely aﬀect tissue perfusion under pathologic conditions
[74,75].
This data conﬁrm the aforementioned assumption that respiratory
function of mitochondria in in vivo SIR-models is impaired by
secondary circulatory failure inducing hypoxia rather than by direct
interaction of inﬂammatory mediators with liver cells. This can explain
the species- and model-speciﬁc diﬀerences in mitochondrial respiration
upon SIR.
Above, we described reports describing mitochondrial morphology/
function determined ex vivo. However, the absence of mitochondrial
dysfunction in ex vivo tests does not necessarily mean that mitochon-
drial function is also not impaired in vivo because inhibition of
mitochondria can be reversible, for instance, by inducing de-phosphor-
ylation of cytochrome c oxidase [76,77] or reversible binding of NO to
cytochrome c oxidase [78]. The performance of mitochondrial oxida-
tive phosphorylation in liver tissue in vivo can be estimated by
measurement of ATP levels.
1.5. ATP levels in tissues upon SIRS
In contrast to reports on mitochondrial morphology and function,
data on ATP levels upon SIR are rather homogeneous, showing a
consistent decrease in ATP levels in diﬀerent tissues. The study on
septic patients carried out by the group of Singer demonstrated that
skeletal muscle ATP concentrations were approximately two times
lower in patients with sepsis who subsequently died compared to septic
patients who survived and to control group; ADP levels were also
increased in non-survivors [3]. Similar diﬀerence in ATP levels was
determined in lymphocytes of septic patients. Survivors had approxi-
mately two times higher ATP levels compared to non-survivors [79].
Also studies performed in various animal models reported a similar
decrease in ATP content in rodents and other species, as well as a
decline in energy charge (deﬁned as [ATP] + 0.5 [ADP]/[AMP]) which
is a more precise measure of bioenergetic status [80]; see also
corresponding references [81–84] in Table 2. Importantly, in contrast
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to mitochondrial respiratory function, there are no clear species speciﬁc
diﬀerences in ATP levels.
In animal models, Hart et al. [83] point out that the results on ATP
levels in sepsis are conﬂicting and appear to be important in more
severe models and may depend on the loss of compensatory mechan-
isms. Duvigneau et al. demonstrated that the changes in ATP levels do
not correlate with the data on respiratory activity of mitochondria
determined ex vivo [91]. It has been shown that the respiratory activity
drops and recovers after LPS injection, but ATP levels drop and do not
recover [91]. This set of data again suggests that mitochondria are
reversibly inhibited in the liver tissue in situ, and that this inhibition is
abolished after their isolation.
There are two methodological explanations for the reversible
inhibition of mitochondrial function in vivo. First, from methodological
considerations, mitochondrial function is tested with saturating
amounts of substrates (e.g. tricarboxylic acid cycle substrates), which
is not the case in vivo. Second, SIR is accompanied by the release of a
number of gas messengers such as NO and carbon monoxide which can
inhibit mitochondria in vivo, but will be substituted by non-physiolo-
gically high oxygen concentrations ex vivo. Irrespective of which
process decreases ATP levels, the question is whether the drop in ATP
levels can cause liver dysfunction.
1.6. ATP levels in other disorders
Summarizing the results discussed to this point, the drop in ATP
levels by a factor of two was the most reproducible change related to
mitochondrial function. The next question is whether or not such a 2-
fold decrease in ATP levels alone is suﬃcient to cause organ/liver
failure observed in SIRS. An approximately 2-fold (40%) drop in ATP
level in liver was observed after partial hepatectomy and was shown to
give a stimulus for regeneration [92]. Of particular interest is the paper
by Latta et al. The authors reduced the levels of ATP to 20% compared
to control levels by an infusion of phosphate-trapping fructose and
tested how ATP depletion inﬂuences the rate of TNF-induced hepato-
cyte death [93]. Unexpectedly, decreased levels of ATP prevented
mitochondrial dysfunction, activation of type II caspases, DNA frag-
mentation, and the levels of apoptotic markers after exposure to TNF
alpha [93], suggesting that partial ATP depletion can be even bene-
ﬁcial.
Intracellular ATP levels play an important role in the crosstalk
between necrosis and apoptosis (reviewed in [94]). However, elevation
of apoptotic markers is not always accompanied by increased occur-
rence of apoptotic cells. In a rat model, severe SIR has been shown to
initiate apoptotic signaling (Bax/Bcl-xL ratio) [56]. Interestingly, the
apoptosis inducing factor was not translocated from mitochondria to
the nucleus suggesting that apoptosis was not executed [56]. In the
same model, ATP levels dropped approximately 2-fold [91], suggesting
that partial ATP depletion might prevent apoptosis.
Probably, partial depletion of ATP, on one hand, can already inhibit
development of apoptosis, while, on the other hand, ATP levels are still
high enough to also prevent necrosis. Induction of apoptosis has been
shown to require ATP levels above 40–50% compared to control levels
[93]. This suggests that a moderate decrease in levels of ATP can be an
adaptive reaction preventing the execution of programmed cell death.
In contrast, nearly full ATP depletion occurs during total liver ischemia,
or incubation of hepatocytes with oligomycin, which increases the
death rate of hepatocytes [95] and induces liver necrosis [96].
Additionally, an approximate 2-fold drop in ATP levels was shown in
erythrocytes of elderly individuals compared to young ones [97],
muscles of patients with Friedrich ataxia [98] and trauma patients
[99]. In our opinion, these results suggest that a mild drop in ATP levels
is likely an unspeciﬁc response to diverse pathological settings which
can be protective rather than deleterious by inhibiting the activation of
apoptosis, in particular, those pathways mediated by mitochondrial
dysfunction.
1.7. Mitochondrial calcium
There is a number of reports suggesting that altered Ca++
metabolism has an impact in SIR [100–102], although impaired
Ca++ metabolism is predominantly associated directly with hypoxia
and ischemia, occurring for instance during transplantation [103]. LPS
treatment has been reported to produce a slight, but signiﬁcant increase
in total hepatic Ca++ content while CLP did not aﬀect this parameter
neither in liver nor in heart, demonstrating a slight Ca++ overload in
endotoxicosis but not in abdominal inﬂammation [104]. It has been
suggested that hepatic intracellular regulation of Ca++ may play a role
in acute inﬂammation [105]. Furthermore, it has been shown that Ca-
ethylenediaminetetraacetic acid (Ca-EDTA) reduces the bacterial bur-
den in liver, suggesting that Ca++ interferes with immune response,
likely stimulating killing of bacteria [106]. In addition, it has been
shown that, upon inﬂammatory stimuli, iNOS is up-regulated in
hepatocytes in a Ca++ dependent manner [107]. On the other hand,
up-regulation of iNOS is driven by ROS too, implying that Ca++
pathway may operate via/ or in a synergistic way with ROS release. The
link between Ca++ and mitochondrial ROS was also suggested by
Rowlands et al. [108]. They provided evidence that controlled TNF
alpha infusion leads to sustained mitochondrial Ca++ elevation and
mitochondrial ROS generation in the pulmonary endothelium. The data
on Ca++ metabolism suggest that Ca++ is not a key player involved in
acute SIR and its involvement is likely mediated by mitochondrial
reactive oxygen species (mtROS).
1.8. Mitochondrial ROS (Fig. 1)
Depending on cell type and state, mitochondria are the major source
of ROS in cells. Primary species generated by mitochondria are super-
oxide radicals (O2•−) and hydrogen peroxide (H2O2), the latter result-
ing from dismutation of two O2•−. Superoxide and H2O2 are not
especially dangerous ROS, but toxic peroxynitrite (ONOO−) can be
formed upon reaction of O2•− with NO, and H2O2 can give rise to toxic
hydroxyl radicals upon reaction with transition metals. In the past,
generation of mitochondrial ROS (mtROS) was only associated with
oxidative stress. In the liver, for instance, excessive generation of
mtROS is associated with the development of non-alcoholic steatohe-
patitis (reviewed in [109]). Recently, ROS were recognized as signaling
molecules in liver and other organs (reviewed in [9,11–14,110]).
Critical role of mitochondrial ROS was suggested for signal transducer
and activator of transcription (STAT) signaling and development of
hepatocellular carcinoma [111,112].
An increasing number of studies demonstrate the essential role of
mtROS in the regulation of the activity of the immune system. It has
been shown that mtROS can modulate activity of NADPH oxidase in
immune cells and in endothelium [113–115], thereby inﬂuencing
bactericidal activity [116]. MtROS are also involved in the production
of inﬂammatory cytokines [117] and in the regulation of T cell
Table 2
Papers reporting decreased ATP levels and energy charge upon SIR in animal models.
Species Model Reference
Rat CLP [85]
Rat Pneumosepsis [86]
Mouse CLP [87]
Pig Severe peritonitis [88]
Pig Peritonitis [89]
Pig Peritonitis [90]
Mouse CLP [81]
Rat LPS [82]
Pig Pseudomonas [83]
Mouse LPS [84]
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activation [118,119] and antigen presentation by Kupﬀer cells [120]. In
the latter study, Kupﬀer cells were either incubated with antioxidants
or inhibitors of NADPH oxidase/xanthine oxidase, or with inhibitors of
the electron transport chain. Each treatment signiﬁcantly decreased T-
cell proliferation in response to antigen presentation by Kupﬀer cells
[120]. These data suggest that also in Kupﬀer cells the activity of
NADPH oxidase is regulated by mtROS.
More recently, it has been shown that mtROS regulate inﬂammatory
response not only in immune cells, but also in hepatocytes. Using direct
detection of mitochondrial ROS and mitochondria targeted antioxi-
dants, Weidinger et al. have demonstrated that mtROS and NO generate
a feed forward loop, so-called NOS-ROS cycle, which is activated by
inﬂammatory mediators and accelerated by mtROS in hepatocytes [69].
NOS providing NO for this cycle is located in cytosol rather than in
mitochondria [121]. Since both O2•− and NO are involved in this cycle,
it is likely that they react to yield ONOO−, which damages hepatocytes
as shown by release of hepatocyte damage markers [69]. Recent reports
revealed that an increase in mtROS production may be due to sustained
activation of c-Jun N-terminal kinase (JNK) pathway [122]. The
activation of the JNK pathway, occurring in liver upon inﬂammation
[123], resulted in inactivation of Src tyrosine kinase on the inner
mitochondrial. This, in turn, inhibits electron transport and increases
ROS release [122]. The STAT3 pathway, another signaling cascade,
occurring upon inﬂammation, inhibits mtROS production [124], and
has been shown to inhibit the opening of the mitochondrial perme-
ability transition pore [125]. Of note, participation of mtROS in
intracellular signaling can be regulated not only by increase in ROS
production but also by the release of ROS into the cytoplasm. It has
been reported that permeability transition pore may regulate the
release of ROS for cellular signaling (reviewed in [126]). Furthermore,
treatment with LPS facilitates the release of ROS from liver mitochon-
dria [127]. These data indicate that mtROS generation is tightly
controlled at diﬀerent levels and, upon release to cytoplasm, accelerate
inﬂammatory reactions.
Thus, the contribution of mtROS to intracellular signaling is
controlled at least three sites, (i) the generation of ROS at the
respiratory chain, (ii) the release of ROS into cytoplasm, and (iii) the
reaction of ROS with targets mediating signal transduction in the
cytoplasm. Below, we consider in details how mtROS generation is
regulated at each of these sites (Fig. 1).
Fig. 1. Mitochondrial ROS-signaling in liver cells upon acute inﬂammation. Pro-inﬂammatory mediators (e.g. TNFα) decrease ATP levels and activate mtROS production, but do not
control directly the release of mtROS in cytoplasm. Anti-inﬂammatory mediators (e.g. IL-4) decrease mtROS generation. The release of mtROS via mPTP is controlled by Ca2+, and ROS
originated from both mitochondria and NOX. In addition, pro-inﬂammatory mediators shift the Bcl/Bax balance in the direction of apoptosis, but the execution of apoptosis is inhibited by
low levels of ATP in hepatocytes. Simultaneously, pro-inﬂammatory mediators up-regulate iNOS thereby increasing NO levels, which activates feed forward loop including mtROS and
iNOS. This loop may also induce oxidative stress if NO and ROS are generated in a great excess. Another feed forward loop includes mtROS and NOX, the latter further accelerates both
mtROS production and NOX activity. Abbreviations: AIF–apoptosis inducing factor, ATP–adenosine triphosphate, Bax–B-cell lymphoma-associated X protein, c-Src–cellular sarcoma, cyt
c–cytochrome c, ER–endoplasmic reticulum; IL–interleukin; INF–interferon; iNOS–inducible nitric oxide synthase, JNK–c-Jun N-terminal kinase, mitoKATP–adenosine triphosphate
sensitive potassium channel, mPTP–mitochondrial permeability transition pore, NO–nitric oxide, NOX–NADPH-oxidase, Ranti-IM–receptors for anti-inﬂammatory mediators, O2–molecular
oxygen, PKC–protein kinase C, ROS–reactive oxygen species, Rpro-IM–receptors for pro-inﬂammatory mediators, STAT-signal transducer and activator of transcription, TNF–tumor
necrosis factor, Δψ–membrane potential, I-IV–complexes I-IV of electron transport chain.
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2. Control of ROS production at the mitochondrial respiratory
chain (Fig. 2)
The primary ROS, the superoxide radical, is produced upon
inﬂammation predominantly at complex I of mitochondrial respiratory
chain. MtROS production is linked to mitochondrial membrane poten-
tial and ATP production. There are four major mechanisms regulating
ROS at respiratory chain upon acute inﬂammation, namely STAT3,
JNK, NO signaling and p66Shc, exerting direct control of mitochondrial
ROS production, interacting with complex I, IV and cytochrome c,
respectively.
2.1. STAT 3
STAT 3 will ﬁrst be phosphorylated by receptor-interacting protein
(RIP) 1 on serine 727 as a result of various activation signals through
extracellular-signal regulated (ERK) 1, ERK2, p38, JNK and mitogen-
activated protein (MAP) kinases [128] (in addition to tyrosine 705
phosphorylation, mediated by Janus kinase (JAK) [129]). This in-
creases its aﬃnity to retinoic-interferon-induced mortality (GRIM)19
and formation of STAT3-GRIM19 complexes. Formed complexes will be
transported to mitochondria and subsequently accumulate at complex I.
Since GRIM19 is a functional element of complex I, this association will
accelerate ATP synthesis and simultaneously decrease ROS formation
(Fig. 2). It has been assumed that not only GRIM19, but also STAT3 is
required for optimal functioning of complex I [130].
2.2. JNK
JNK 1–3 are members of the MAP kinase family and are activated by
a wide range of pro-inﬂammatory cytokines, such as TNF-alpha and
interleukin (IL)-1 (reviewed in [131]). The best characterized pathway
of JNK activation is the TNF-TNF receptor type (TNFR)1 cascade. The
formation of TNF-TNFR1 (Fig. 1) rapidly activates JNK. Activated
(phosphorylated) JNK forms a protein complex with MAP kinase kinase
(MKK)4, Sab and Bax in the outer mitochondrial membrane [132]
(Fig. 2).
Phosphorylation of Sab by p-JNK leads to dephosphorylation of Src
in the inner mitochondrial membrane, presumably by a src homology 1
domain containing protein tyrosine phosphatase (SHP1)-dependent
mechanism [122]. Consequently, mitochondrial respiratory capacity
declines and ROS production rises, leading to sustained activation of
JNK-signaling by a self-sustaining circle, ultimately resulting in high
ROS levels and subsequent mitochondrial permeability transition pore
opening.
An additional regulatory pathway is exerted by JNK through the
activation of p66Shc, an alternatively spliced transcript from gene
SHC1. It was ﬁrst published in 2005 that p66Shc can produce ROS
acting as an oxidoreductase and transferring electrons from mitochon-
drial cytochrome c to molecular oxygen, producing ROS [133]. The role
of p66Shc was shown so far in hypoxia-reoxygenation and pathological
states associated with elevated ROS levels. The role of mitochondrial
p66Shc was postulated in the ROS-induced ROS release [134,135],
leading ultimately to induction of mitochondrial permeability transi-
tion.
2.3. NO
Nitric oxide interacts with complex I [136] and complex IV [137] of
the mitochondrial respiratory chain. The inhibition of electron ﬂow
through the respiratory chain from either NADH or succinate to
molecular oxygen causes electron accumulation in the electron trans-
port chain. This increases the probability of electron leak from
respiratory chain and one-electron reduction of oxygen yielding O2•−
[138]. Simultaneously with increased O2•− generation, the inhibition of
electron transfer also decreases membrane potential and consequently
ATP synthesis in mitochondria [139].
3. Control of ROS release to cytoplasm (Fig. 3)
The regulation of ROS release into cytoplasm is controlled by two
distinct mechanisms, namely the Ca++- and ROS- mediated ROS
release into cytoplasm. Both mechanisms are realized by ROS diﬀusion
via opened mPTP (Fig. 3). The exact structure of the mPTP is not yet
clariﬁed, although there are diﬀerent models. In the ﬁrst model, the
mPTP is formed at the adenine nucleotide translocator (ANT). The ANT
is the most abundant protein in the inner mitochondrial membrane,
transporting ATP out of mitochondria and ADP back into the matrix.
Fig. 2. Interaction of regulatory factors with ATP and ROS production of the
mitochondrial electron transport chain. At least three major signaling pathways
(STAT3, JNK and NO) regulate mtROS production under acute inﬂammation. Signal
transducer and activator of transcription protein 3 is activated by phosphorylation by
Janus Kinase (JAK) proteins. After phosphorylation, STAT3 binds directly to GRIM-19, a
subunit of mitochondrial ETC complex I, and is then transported into mitochondria,
where it enhances activity of complex I, thereby enhancing ATP synthesis, and reduces
ROS production. Phosphorylated JNK1/2 forms a complex in the outer mitochondrial
membrane with MKK4, Bax and Sab. Then, this signal will be transmitted to the inner
mitochondrial membrane by SHP1, which decreases complex IV protein phosphorylation
causing a decrease in ATP synthesis and an increase in ROS production. As a third
pathway, nitric oxide and peroxynitrite are able to directly inhibit complex I and IV
causing a drop in ATP levels, and increase ROS formation. Abbreviations: ATP–adenosine
triphosphate, Bax– B-cell lymphoma-associated X protein, cyt c–cytochrome c, GRIM-
19–gene associated with retinoid interferon induced cell mortality 19, H2O2–hydrogen
peroxide, IMM–inner mitochondrial membrane, IMS–intermembrane space, JNK–cJun N-
terminal kinase, MKK–mitogen-activated protein kinase kinase, NO–nitric oxide,
ONOO–peroxynitrite, O2•-–superoxide radical, O2–molecular oxygen, OMM–outer mito-
chondrial membrane, Q–Q-cycle, Sab–SH3BP5, STAT–signal transducer and activator of
transcription, CI-CV–mitochondrial electron transport chain complex I–V.
A.V. Kozlov et al. Redox Biology 13 (2017) 170–181
175
Diﬀerent reports suggest that this channel consist of two ANT units or of
one ANT and one phosphate carrier (PiC) unit (reviewed in [140]).
More recently, it has been suggested that not the ANT but the F-ATP
synthase (Fig. 3a) forms the mPTP channel [141]. This assumption is
supported by the fact that, in the absence of ANT, the formation of the
mPTP can be detected [142].
3.1. ROS induced ROS release
It has been shown that, upon inﬂammation, complex I generates
substantially more ROS than at normal conditions [4] and induces the
formation of mPTP. As a result, mtROS are released to the cytoplasm
via mPTP. This phenomenon is called ROS-induced ROS release. There
are, at least, three targets of oxidative agents contributing to increased
probability to mPTP opening (Fig. 3b). The ﬁrst class of cysteines,
termed as ‘S-site’ is associated with the voltage sensor of the mPTP,
where vicinal SH groups on cysteine residues can be oxidized or
reduced (probably through glutathione on the matrix side of IMM)
[143]. The second target, called ‘P-site’, is modulated by the oxidation-
reduction state of pyridine nucleotides [144]. Finally, an additional site
of action was described by Costantini et al. [145], as part of a two-step
reaction. In this reaction, SH groups, located most probably on the
outer surface of IMM, react with oxidants, which subsequently expose a
thiol group for a second oxidation step, modulating the mPTP opening
directly.
3.2. Ca++ mediated ROS release
The pore-forming mitochondrial F-ATP synthase could also be
activated by Ca++ [146]. The critical component of this mechanism
is mitochondrial cyclophilin (CyP)-D exhibiting peptidyl-prolyl cis–-
trans isomerase activity. Pi facilitates the binding of CyP-D to the F-ATP
synthase, thereby converting it to a non-speciﬁc pore, which enables
mtROS to be released into the cytoplasm. [146] (Fig. 3c). It has been
suggested that a decrease in the membrane potential, induced by NO or
other factors (Fig. 1) can also open the mPTP [147].
4. Activation of signaling pathways (Fig. 4)
As mentioned above, the two major pathways regulated by mtROS
Fig. 3. Mechanism regulating reactive oxygen species release into cytoplasm. Under normal conditions, mPTP is impermeable (A). Under inﬂammatory and other pathologic
conditions, two pathways are repeatedly described in the literature. The ﬁrst one is ROS-dependent ROS release (B). Elevated ROS levels facilitate oxidation of cysteines at diﬀerent sites
of mitochondrial F-ATP synthase. The ﬁrst, called S-site, is associated with the voltage sensor of the mPTP. The second, termed as “P-site”, can be aﬀected by oxidation-reduction state of
pyridine nucleotides. An additional site is located on the outer surface of the inner mitochondrial membrane (here indicated as “O”) which can modulate the mPTP opening in a two-step
reaction. The second mechanism is Ca++-dependent (C). Increased concentrations of Ca++ and cyclophilin D convert the F-ATP synthase to a non-speciﬁc pore which facilitates the
release of ROS from mitochondria to the cytosol. Phosphorylated STAT3 can inhibit the opening of the mitochondrial permeability transition pore by binding to Cyp D. Abbreviations:
ATP—adenosine triphosphate, Cyp D—cyclophilin D, ROS—reactive oxygen species.
A.V. Kozlov et al. Redox Biology 13 (2017) 170–181
176
in liver are the activation of NADPH oxidase and up-regulation of
several inﬂammatory genes. These signaling pathways are turned on by
two kinases, PKC and c-Src tyrosine kinase (c-Src). Both kinases are
located in the cytoplasm and can be activated by ROS. Thus, the
interaction between ROS and kinases is the third and the last phase
involving mtROS mediated activation of signaling cascades. Logically,
this phase is dependent on the concentration and availability of kinases
in single types of cells and can also be inﬂuenced by endogenous
antioxidant systems. The activation of kinases by ROS is based on the
reaction with speciﬁc SH groups of PKC and c-Src. This reaction can be
catalyzed by superoxide, hydrogen peroxide and other ROS. It has been
shown that thiyl radicals are intermediates of this interaction. Thiyl
radicals further generate ROS, suggesting that the reaction between
protein thiols and ROS is a speciﬁc signaling interaction, which does
not inﬂuence antioxidant capacity of the cells [148] (Fig. 4).
4.1. ROS induced activation of PKC
PKC has a unique structure containing two domains, regulatory and
catalytic, and has two types of cysteine-rich regions present in both
domains. Critical for activation are the cysteine-rich domain-binding
zinc atoms, keeping PKC in an inactive conﬁguration. Oxidative
modiﬁcation of these groups by ROS causes the so-called cofactor
independent activation of PKC, which becomes able to phosphorylate
target proteins [149]. However, further increase in ROS levels causing
modiﬁcation of SH residues in catalytic center can inactivate PKC
(reviewed in [150]).
4.2. ROS induced activation of c-Src
It has been shown that c-Src can be activated by two mechanisms
linked to the formation of ROS, namely those mediated by NO and ROS.
c-Src tyrosine kinase contains three major domains, the catalytic
domain, and SH2 and SH3, domains critical for the activation of
enzyme. The inactive enzyme occurs in a “closed form” which does
neither allow interacting with downstream proteins at SH2 and SH3
domains nor executing kinase activity at the catalytic domain. This
“closed conﬁguration” can be turned in the active form by NO [151].
NO nitrosylates Cys498, which forms a link between SH2 and catalytic
domain. In this conﬁguration, the SH2 and SH3 domains are enabled to
bind downstream signaling proteins and the catalytic domain phos-
phorylates them [151]. Another ROS-mediated mechanism linking SH2
and catalytic domain includes ROS-mediated oxidation of SH groups of
Cys245 located in SH2 and Cys487 located in catalytic domain. Cys245
and Cys487 form an S-S bridge activating the enzyme [152].
5. Conclusion
The available literature does not uniformly report changes in
mitochondrial structure and major functions upon acute inﬂammation.
Inﬂammation does only slightly and reversibly inhibit mitochondrial
respiratory function, causing an approximate 2-fold decrease in tissue
ATP levels. This decrease seems to be suﬃcient to inhibit apoptosis, but
not suﬃcient to induce acute necrotic cell death, although in the long
run, upon chronic inﬂammation, this may lead to pathological changes
in liver metabolism. We assume that necrotic cell death arises from
Fig. 4. Mechanism of ROS-mediated signaling pathways in cytoplasm. Upon inﬂammation, ROS predominantly activate two kinases, PKC and c-Src. Under normal conditions, PKC is
kept in an inactive “closed” conﬁguration. The zinc ﬁnger at the regulatory unit, a complex between SH groups and zinc atoms, deﬁnes this conﬁguration, which does not allow
phosphorylation. ROS can interact with SH groups, thereby disrupting this binding. This results in the release of zinc (A) and activation (B) of PKC. Similar to PKC, c-Src is inactive under
normal conditions. In this catalytically inactive conformation, the kinase domain of c-Src interacts with the SH2-domain (C). The activation of c-Src may occur through S-nitrosylation of
cysteine 498 of kinase domain by NO (D) or intermolecular disulﬁde bond formation between cysteine 245 and cysteine 487 by ROS (E). ROS oxidize these SH groups linking catalytic
domain and SH2 by means of S-S bridge (E). Abbreviations: cat—catalytic subunit, cys—cysteine, H2O2—hydrogen peroxide, NO—nitric oxide, reg—regulatory subunit, SH—Src
homolog.
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profound impairment of mitochondrial function as a result of secondary
to inﬂammation circulation failure followed by hypoxia. MtROS rather
than low ATP levels contribute to acute liver failure induced by
inﬂammation. MtROS are acting either via intracellular signaling
cascades, or via induction of oxidative stress, damaging intracellular
structures. The available literature suggests that signaling cascades,
such as feed forward activation of NADPH-oxidase and up-regulation of
inﬂammatory genes (ROS-NOS cycle) play a predominant role in
inﬂammation-related action of mtROS. ONOO−, which escapes from
the ROS-NOS cycle, and free iron, released from intracellular depots,
seem to be the major pro-oxidants operating upon inﬂammation and
hypoxia, respectively. The signaling action of mtROS is strictly con-
trolled at, at least, three points, (i) at the site of ROS generation at
complex I, (ii) the site of mtROS release in cytoplasm via permeability
transition pore, and (iii) interaction with speciﬁc kinases in cytoplasm.
The systems controlling mtROS-signaling include pro- and anti-inﬂam-
matory mediators, nitric oxide, Ca++ and NADPH-oxidase. This review
highlights mitochondria-dependent mechanisms that may be associated
with liver failure upon acute inﬂammation. However, further liver cell-
speciﬁc studies on mtROS signaling are necessary to translate these data
into clinical practice, in order to develop mitochondria-targeted
diagnostic and therapeutic approaches.
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